George Gilder

The costs of institutional health care failure now gorge nearly 15% of GDP, on the way to 20%. Yet the costs of the forward-looking genetic information in biomedicine has dropped 50,000-fold in ten years. What’s wrong with this picture? To paymaster politicians, health care is a huge cost center. Health care is not really a problem but a huge opportunity for new drugs, medical instruments and biomedical advances. No U.S. health care cost crisis looms, after all, in paying the bills for smallpox, polio, TB, cholera, typhoid or malaria. Obscuring the huge opportunity of new knowledge in pharma, though, is the obsolete apparat of government power. With 16,500 new IRS agents and no new doctors, ObamaCare pushes on with its bureaucratic Read More ›